InflaRx Past Earnings Performance
Past criteria checks 0/6
InflaRx's earnings have been declining at an average annual rate of -9%, while the Biotechs industry saw earnings growing at 16.9% annually.
Key information
-9.0%
Earnings growth rate
20.2%
EPS growth rate
| Biotechs Industry Growth | -14.6% |
| Revenue growth rate | n/a |
| Return on equity | -34.3% |
| Net Margin | n/a |
| Last Earnings Update | 30 Sep 2022 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How InflaRx makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 22 | 0 | -34 | 15 | 39 |
| 30 Jun 22 | 0 | -38 | 15 | 41 |
| 31 Mar 22 | 0 | -54 | 13 | 41 |
| 31 Dec 21 | 0 | -46 | 12 | 36 |
| 30 Sep 21 | 0 | -42 | 12 | 31 |
| 30 Jun 21 | 0 | -37 | 9 | 27 |
| 31 Mar 21 | 0 | -32 | 9 | 23 |
| 31 Dec 20 | 0 | -34 | 8 | 26 |
| 30 Sep 20 | 0 | -39 | 9 | 31 |
| 30 Jun 20 | 0 | -46 | 10 | 39 |
| 31 Mar 20 | 0 | -52 | 12 | 44 |
| 31 Dec 19 | 0 | -53 | 13 | 45 |
| 30 Sep 19 | 0 | -50 | 13 | 43 |
| 30 Jun 19 | 0 | -42 | 14 | 35 |
| 31 Mar 19 | 0 | -29 | 13 | 27 |
| 31 Dec 18 | 0 | -30 | 13 | 25 |
| 30 Sep 18 | 0 | -31 | 12 | 22 |
| 30 Jun 18 | 0 | -29 | 10 | 19 |
| 31 Mar 18 | 0 | -31 | 8 | 17 |
| 31 Dec 17 | 0 | -24 | 5 | 14 |
| 30 Sep 17 | 0 | -17 | 3 | 11 |
| 30 Jun 17 | 0 | -15 | 3 | 9 |
| 31 Mar 17 | 0 | -12 | 2 | 7 |
| 31 Dec 16 | 0 | -9 | 2 | 5 |
Quality Earnings: IF0 is currently unprofitable.
Growing Profit Margin: IF0 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: IF0 is unprofitable, and losses have increased over the past 5 years at a rate of 9% per year.
Accelerating Growth: Unable to compare IF0's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: IF0 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-26.8%).
Return on Equity
High ROE: IF0 has a negative Return on Equity (-34.32%), as it is currently unprofitable.